Mostafa Akbarzadeh-Khiavi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mostafa Akbarzadeh-Khiavi has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Azam Safary
Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
18 shared publications - Yadollah Omidi
Department of Pharmaceutical Sciences, Barry and Judy Silverman College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL, 33328, USA
8 shared publications Hamed Farzi-Khajeh
Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
4 shared publications- Jaleh Barar
Department of Pharmaceutical Sciences, Barry and Judy Silverman College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL 33328, USA
4 shared publications Azam Safary
Research Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran
3 shared publications- Khosro Adibkia
Research Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran; Department of Pharmaceutics, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
3 shared publications
Latest Publications
- Open Access
- 11 November 2026
- Published by Springer Nature in Scientific Reports
lncRNA PVT1 and STAT3 are coordinately upregulated in Behçet’s disease and associated with disease activity
- 11 November 2026
- Published by Springer Nature in Scientific Reports
Open AccesslncRNA PVT1 and STAT3 are coordinately upregulated in Behçet’s disease and associated with disease activity
- 15 June 2026
- Published by Maad Rayan Publishing Company in Advanced Pharmaceutical Bulletin
Translational Landscape of Nanopharmaceuticals: Progress and Prospects on Biomacromolecule Delivery and Active Targeting
Over the past two decades, nanopharmaceuticals have demonstrated strong potential for biomacromolecule delivery, yet clinical translation remains scarce. This study examines the persistent gap between laboratory research and clinical application, drawing on practical lessons from enzyme-conjugated nanoparticles, EGFR-targeted gold nanoparticles, and magnetic nanobiosystems. Although multifunctional nanocarriers excel in vitro, their clinical success is often hindered by biological factors that are frequently neglected in laboratory studies. These issues include protein corona formation, which diminishes targeting specificity; complexities in optimizing ligand density; challenges in scaling up manufacturing; and regulatory hurdles. The protein corona, forming immediately after biological exposure, fundamentally alters nanoparticle identity and targeting in clinical environments. Moreover, complex multi-component designs often fail to translate due to batch variability and excessive production costs. This study advocates prioritizing design principles that emphasize manufacturability, biological robustness, and regulatory practicality over technological novelty. By applying insights from two decades of translational barriers, the field can advance toward clinically viable nanopharmaceutical platforms through simplified designs that address real-world limitations.
- 15 June 2026
- Published by Maad Rayan Publishing Company in Advanced Pharmaceutical Bulletin
Translational Landscape of Nanopharmaceuticals: Progress and Prospects on Biomacromolecule Delivery and Active Targeting
Over the past two decades, nanopharmaceuticals have demonstrated strong potential for biomacromolecule delivery, yet clinical translation remains scarce. This study examines the persistent gap between laboratory research and clinical application, drawing on practical lessons from enzyme-conjugated nanoparticles, EGFR-targeted gold nanoparticles, and magnetic nanobiosystems. Although multifunctional nanocarriers excel in vitro, their clinical success is often hindered by biological factors that are frequently neglected in laboratory studies. These issues include protein corona formation, which diminishes targeting specificity; complexities in optimizing ligand density; challenges in scaling up manufacturing; and regulatory hurdles. The protein corona, forming immediately after biological exposure, fundamentally alters nanoparticle identity and targeting in clinical environments. Moreover, complex multi-component designs often fail to translate due to batch variability and excessive production costs. This study advocates prioritizing design principles that emphasize manufacturability, biological robustness, and regulatory practicality over technological novelty. By applying insights from two decades of translational barriers, the field can advance toward clinically viable nanopharmaceutical platforms through simplified designs that address real-world limitations.
- 10 May 2026
- Published by Maad Rayan Publishing Company in Advanced Pharmaceutical Bulletin
- Vol. 16 (2) , 332-342
Next-Generation Targeted Molecular Therapies in Immune-Mediated Inflammatory Diseases
Immune-mediated inflammatory diseases (IMIDs) are chronic disorders characterized by dysregulated immunity and loss of self-tolerance. Although significant progress has been made in the management of IMIDs, challenges such as drug resistance, immunogenicity, and limited accessibility continue to impede clinical outcomes. Achieving sustained remission necessitates a transition toward precision medicine that addresses fundamental disease mechanisms. This study examines recent advances in molecular interventions, including cytokine inhibitors, kinase modulators, and B-cell therapies, and emphasizes how these approaches improve remission rates and reduce relapses. Additionally, emerging platforms such as RNA therapeutics, nanomedicine, and chimeric antigen receptor (CAR) cell therapies are discussed, with a focus on their potential to enhance efficacy and prolong clinical response duration. Integrating these innovations with artificial intelligence to identify therapeutic targets, predict patient responses, and optimize drug development is essential to realizing truly personalized, more successful treatments for IMIDs.
- 10 May 2026
- Published by Maad Rayan Publishing Company in Advanced Pharmaceutical Bulletin
- Vol. 16 (2) , 332-342
Next-Generation Targeted Molecular Therapies in Immune-Mediated Inflammatory Diseases
Immune-mediated inflammatory diseases (IMIDs) are chronic disorders characterized by dysregulated immunity and loss of self-tolerance. Although significant progress has been made in the management of IMIDs, challenges such as drug resistance, immunogenicity, and limited accessibility continue to impede clinical outcomes. Achieving sustained remission necessitates a transition toward precision medicine that addresses fundamental disease mechanisms. This study examines recent advances in molecular interventions, including cytokine inhibitors, kinase modulators, and B-cell therapies, and emphasizes how these approaches improve remission rates and reduce relapses. Additionally, emerging platforms such as RNA therapeutics, nanomedicine, and chimeric antigen receptor (CAR) cell therapies are discussed, with a focus on their potential to enhance efficacy and prolong clinical response duration. Integrating these innovations with artificial intelligence to identify therapeutic targets, predict patient responses, and optimize drug development is essential to realizing truly personalized, more successful treatments for IMIDs.
- 16 June 2025
- Published by Maad Rayan Publishing Company in Medical Journal of Tabriz University of Medical Sciences
- Vol. 47 (3) , 274-286
Effect of nano-formulated Panitumumab on AKT/PTEN/caspase 3 apoptosis and gene expression and BAX/Bcl2 signaling pathway in KRAS-mutant SW480 cells
Background. This study aims to design and synthesize a nanostructure to address drug resistance in colorectal cancer cells. Specifically, it targets cells with mutations in the KRAS gene that resist the chemotherapy drug, Panitumumab. Then, the biological effects of this nanostructure were investigated in colorectal cancer cells (SW480). Methods. The targeted nanostructure was composed of PEGylated gold nanoparticles conjugated to Panitumumab (GNP-PEG-Pan), and its physicochemical properties were determined. The cytotoxic effects of this nanostructure on SW480 cells were assessed using the MTT assay technique. The effect of this nanostructure on apoptosis in cancer cells was evaluated using flow cytometry techniques. The expression levels of genes involved in apoptosis, including AKT, PTEN, Bax, Bcl2, and Caspase 3, were evaluated after the application of the targeted nanostructure using Real-time PCR techniques. Results. The results of the study indicated cytotoxic and apoptotic effects of the targeted nanostructure against SW480 cells and overcoming drug resistance in this cell line. This targeted nanostructure played a key role in inducing apoptosis in KRAS mutant colorectal cancer cells by increasing the expression of PTEN, Bax, and caspase 3 genes and decreasing the expression of the AKT and Bcl2 genes. Conclusion. Our findings demonstrated that the engineered nanostructure can inhibit cell proliferation and induce apoptosis in KRAS mutant colorectal cancer cells. Therefore, this nano-formulated antibody can be proposed as a novel therapeutic option for colorectal cancer and other solid tumors. Practical Implications. The engineered targeted nanostructure (GNP-PEG-Pan) enhances cytotoxic effects and induces apoptosis in KRAS-mutant CRC cells resistant to Panitumumab.
- 16 June 2025
- Published by Maad Rayan Publishing Company in Medical Journal of Tabriz University of Medical Sciences
- Vol. 47 (3) , 274-286
Effect of nano-formulated Panitumumab on AKT/PTEN/caspase 3 apoptosis and gene expression and BAX/Bcl2 signaling pathway in KRAS-mutant SW480 cells
Background. This study aims to design and synthesize a nanostructure to address drug resistance in colorectal cancer cells. Specifically, it targets cells with mutations in the KRAS gene that resist the chemotherapy drug, Panitumumab. Then, the biological effects of this nanostructure were investigated in colorectal cancer cells (SW480). Methods. The targeted nanostructure was composed of PEGylated gold nanoparticles conjugated to Panitumumab (GNP-PEG-Pan), and its physicochemical properties were determined. The cytotoxic effects of this nanostructure on SW480 cells were assessed using the MTT assay technique. The effect of this nanostructure on apoptosis in cancer cells was evaluated using flow cytometry techniques. The expression levels of genes involved in apoptosis, including AKT, PTEN, Bax, Bcl2, and Caspase 3, were evaluated after the application of the targeted nanostructure using Real-time PCR techniques. Results. The results of the study indicated cytotoxic and apoptotic effects of the targeted nanostructure against SW480 cells and overcoming drug resistance in this cell line. This targeted nanostructure played a key role in inducing apoptosis in KRAS mutant colorectal cancer cells by increasing the expression of PTEN, Bax, and caspase 3 genes and decreasing the expression of the AKT and Bcl2 genes. Conclusion. Our findings demonstrated that the engineered nanostructure can inhibit cell proliferation and induce apoptosis in KRAS mutant colorectal cancer cells. Therefore, this nano-formulated antibody can be proposed as a novel therapeutic option for colorectal cancer and other solid tumors. Practical Implications. The engineered targeted nanostructure (GNP-PEG-Pan) enhances cytotoxic effects and induces apoptosis in KRAS-mutant CRC cells resistant to Panitumumab.
- Open Access
- 26 May 2025
- Published by Maad Rayan Publishing Company in BioImpacts
- Vol. 15 (1) , 30867
Anticancer impacts of the unicellular cyanobacterium Chroococcus turgidus bioactive compounds in colorectal adenocarcinoma
Introduction: Microalgae and cyanobacteria are promising sources of bioactive compounds with antioxidant and anticancer properties. The cyanobacterium Chroococcus turgidus has been studied for its potential antioxidant, anti-inflammatory, antibacterial, antiviral, and anticancer effects. This study investigates its anticancer effects on colorectal cancer (CRC) at the cellular and molecular levels. Methods: The metabolites of C. turgidus were screened using the Folin–Ciocalteu reagent and GC-MS. Antioxidant activity was assessed using the DPPH assay. The biological effects of methanolic extract (ME) were evaluated using MTT assay, Annexin V/PI staining, DAPI staining, and western blotting. Cells were treated with ME at concentrations ranging from 5 to 500 µg/mL for 24 and 48 hours, with the IC50 values determined at 373 µg/mL and 291 µg/mL, respectively. Results: ME contained bioactive compounds such as phenols, flavonoids, and anthocyanins. Identified fatty acids included palmitic acid ethyl ester (15.53%), 1-bromo-11-iodoundecane (2.31%), undecanoic acid 2,8-dimethyl methyl ester (6.62%), oleic acid (6.47%), and 7-dehydrocholesterol (7.97%). ME inhibited SW480 cell proliferation in a dose- and time-dependent manner and induced nuclear fragmentation, chromatin remodeling, and apoptosis. Annexin V/PI staining confirmed apoptosis as the dominant mode of cell death. Western blot analysis showed increased Bax and decreased Bcl2 expression, supporting its pro-apoptotic activity. Conclusion: C. turgidus may serve as a potential therapeutic agent for gastrointestinal cancers through its ability to modulate the Bax/Bcl2 pathway and promote apoptosis. These findings highlight its novel anticancer effects and support further preclinical investigations.
- 26 May 2025
- Published by Maad Rayan Publishing Company in BioImpacts
- Vol. 15 (1) , 30867
Open AccessAnticancer impacts of the unicellular cyanobacterium Chroococcus turgidus bioactive compounds in colorectal adenocarcinoma
Introduction: Microalgae and cyanobacteria are promising sources of bioactive compounds with antioxidant and anticancer properties. The cyanobacterium Chroococcus turgidus has been studied for its potential antioxidant, anti-inflammatory, antibacterial, antiviral, and anticancer effects. This study investigates its anticancer effects on colorectal cancer (CRC) at the cellular and molecular levels. Methods: The metabolites of C. turgidus were screened using the Folin–Ciocalteu reagent and GC-MS. Antioxidant activity was assessed using the DPPH assay. The biological effects of methanolic extract (ME) were evaluated using MTT assay, Annexin V/PI staining, DAPI staining, and western blotting. Cells were treated with ME at concentrations ranging from 5 to 500 µg/mL for 24 and 48 hours, with the IC50 values determined at 373 µg/mL and 291 µg/mL, respectively. Results: ME contained bioactive compounds such as phenols, flavonoids, and anthocyanins. Identified fatty acids included palmitic acid ethyl ester (15.53%), 1-bromo-11-iodoundecane (2.31%), undecanoic acid 2,8-dimethyl methyl ester (6.62%), oleic acid (6.47%), and 7-dehydrocholesterol (7.97%). ME inhibited SW480 cell proliferation in a dose- and time-dependent manner and induced nuclear fragmentation, chromatin remodeling, and apoptosis. Annexin V/PI staining confirmed apoptosis as the dominant mode of cell death. Western blot analysis showed increased Bax and decreased Bcl2 expression, supporting its pro-apoptotic activity. Conclusion: C. turgidus may serve as a potential therapeutic agent for gastrointestinal cancers through its ability to modulate the Bax/Bcl2 pathway and promote apoptosis. These findings highlight its novel anticancer effects and support further preclinical investigations.
- Open Access
- 9 January 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-16
EGFR-targeting RNase A-cetuximab antibody-drug conjugate induces ROS-mediated apoptosis to overcome drug resistance in KRAS mutant cancer cells
Antibody-drug conjugates (ADCs) are an emerging strategy in cancer therapy, enhancing precision and efficacy by linking targeted antibodies to potent cytotoxic agents. This study introduces a novel ADC that combines ribonuclease A (RNase A) with cetuximab (Cet), an anti-EGFR monoclonal antibody, through a polyethylene glycol (PEG) linker (RN-PEG-Cet), aimed to induce apoptosis in KRAS mutant colorectal cancer (CRC) via a ROS-mediated pathway. RN-PEG-Cet was successfully synthesized and characterized for its physicochemical properties, retaining full enzymatic activity in RNA degradation and high binding affinity to EGFR. In KRAS mutant SW-480 cells, RN-PEG-Cet significantly reduced cell viability at lower doses, with an IC50 of 11.7 µg/mL at 72 h. Compared to free Cet, RN-PEG-Cet demonstrated a ~ 2-fold increase in apoptosis and a ~ 3.5-fold increase in ROS production. The conjugate also disrupted the Nrf2/Keap1 pathway, with a significant upregulation of Keap1 (FC = 3.7, p ≤ 0.01) and downregulation of Nrf2 (FC = 3.3, p < 0.01), highlighting its role in impairing antioxidant defenses and promoting ROS-mediated cytotoxicity. These findings emphasize the potential of RN-PEG-Cet as a novel therapeutic approach for KRAS mutant CRC, offering superior apoptosis induction and targeted cytotoxicity compared to conventional therapies. This ADC could represent a new strategy for improving CRC treatment outcomes by effectively overcoming resistance mechanisms.
- 9 January 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-16
Open AccessEGFR-targeting RNase A-cetuximab antibody-drug conjugate induces ROS-mediated apoptosis to overcome drug resistance in KRAS mutant cancer cells
Antibody-drug conjugates (ADCs) are an emerging strategy in cancer therapy, enhancing precision and efficacy by linking targeted antibodies to potent cytotoxic agents. This study introduces a novel ADC that combines ribonuclease A (RNase A) with cetuximab (Cet), an anti-EGFR monoclonal antibody, through a polyethylene glycol (PEG) linker (RN-PEG-Cet), aimed to induce apoptosis in KRAS mutant colorectal cancer (CRC) via a ROS-mediated pathway. RN-PEG-Cet was successfully synthesized and characterized for its physicochemical properties, retaining full enzymatic activity in RNA degradation and high binding affinity to EGFR. In KRAS mutant SW-480 cells, RN-PEG-Cet significantly reduced cell viability at lower doses, with an IC50 of 11.7 µg/mL at 72 h. Compared to free Cet, RN-PEG-Cet demonstrated a ~ 2-fold increase in apoptosis and a ~ 3.5-fold increase in ROS production. The conjugate also disrupted the Nrf2/Keap1 pathway, with a significant upregulation of Keap1 (FC = 3.7, p ≤ 0.01) and downregulation of Nrf2 (FC = 3.3, p < 0.01), highlighting its role in impairing antioxidant defenses and promoting ROS-mediated cytotoxicity. These findings emphasize the potential of RN-PEG-Cet as a novel therapeutic approach for KRAS mutant CRC, offering superior apoptosis induction and targeted cytotoxicity compared to conventional therapies. This ADC could represent a new strategy for improving CRC treatment outcomes by effectively overcoming resistance mechanisms.
- 14 July 2024
- Published by Elsevier in Process Biochemistry
- Vol. 146, 56-67
Immobilized recombinant laccase over PEGylated silica-coated magnetic nanoparticles for anti-inflammatory modulation in pro-monocytic model cell line
- 14 July 2024
- Published by Elsevier in Process Biochemistry
- Vol. 146, 56-67
Immobilized recombinant laccase over PEGylated silica-coated magnetic nanoparticles for anti-inflammatory modulation in pro-monocytic model cell line
- Open Access
- 6 July 2024
- Published by Maad Rayan Publishing Company in Pharmaceutical Sciences
- Vol. 30 (4) , 444-455
Improved Biological Impacts of Anti-EGFR Monoclonal Antibody in KRAS-Mutant Colorectal Cancer Cells by Silica-Coated Magnetic Nanoparticle Conjugation
Background: The therapeutic potential of epidermal growth factor receptor (EGFR) targeting in colorectal cancer (CRC) is hindered by the presence of KRAS codon 12 activating mutations, prevalent in approximately 25% of advanced CRC cases. This study investigates the role of reactive oxygen species (ROS) in conferring resistance to anti-EGFR monoclonal antibodies in KRAS mutant CRC cells, focusing on ROS-mediated apoptosis induction using cetuximab-PEGylated silica-coated magnetic nanoparticles (MNPs). Methods: MNPs were synthesized and surface-coated with silica, followed by functionalization and stabilization with polyethylene glycol (PEG). Cetuximab (Cet) was covalently conjugated to generate EMNP-PEG-Cet. Structural and compositional analyses were performed using scanning electron microscopy (SEM), dynamic light scattering (DLS), UV-vis spectroscopy, and Fourier transform infrared (FTIR) analysis. Apoptosis induction, chromatin condensation, and ROS production were evaluated in KRAS mutant SW-480 CRC cells. Results: Successful synthesis of EMNP-PEG-Cet was confirmed, revealing a particle size of 67 nm and a surface charge of -8.3 mV. The conjugate exhibited significant cytotoxicity against CRC cells, with notable apoptosis induction and ROS generation in EGFR-positive/KRAS mutant SW-480 cells, surpassing the effects observed with bare Cet and EMNP-PEG controls. The nuclear factor erythroid 2-related factor 2/Kelch-like ECH-related protein 1 (Nrf2-Kaep1) gene expression analysis by real-time PCR showed that cells treated with EMNP-PEG-Cet exhibited a noteworthy decrease in Nrf2 expression and a simultaneous increase in Keap1 expression compared to those treated with free Cet. Conclusion: These findings highlight the potential of ROS-mediated apoptosis induction to enhance the cytotoxicity of Cet in EGFR-positive/KRAS mutant CRC cells, offering new avenues for overcoming drug resistance mechanisms in metastatic CRC.
- 6 July 2024
- Published by Maad Rayan Publishing Company in Pharmaceutical Sciences
- Vol. 30 (4) , 444-455
Open AccessImproved Biological Impacts of Anti-EGFR Monoclonal Antibody in KRAS-Mutant Colorectal Cancer Cells by Silica-Coated Magnetic Nanoparticle Conjugation
Background: The therapeutic potential of epidermal growth factor receptor (EGFR) targeting in colorectal cancer (CRC) is hindered by the presence of KRAS codon 12 activating mutations, prevalent in approximately 25% of advanced CRC cases. This study investigates the role of reactive oxygen species (ROS) in conferring resistance to anti-EGFR monoclonal antibodies in KRAS mutant CRC cells, focusing on ROS-mediated apoptosis induction using cetuximab-PEGylated silica-coated magnetic nanoparticles (MNPs). Methods: MNPs were synthesized and surface-coated with silica, followed by functionalization and stabilization with polyethylene glycol (PEG). Cetuximab (Cet) was covalently conjugated to generate EMNP-PEG-Cet. Structural and compositional analyses were performed using scanning electron microscopy (SEM), dynamic light scattering (DLS), UV-vis spectroscopy, and Fourier transform infrared (FTIR) analysis. Apoptosis induction, chromatin condensation, and ROS production were evaluated in KRAS mutant SW-480 CRC cells. Results: Successful synthesis of EMNP-PEG-Cet was confirmed, revealing a particle size of 67 nm and a surface charge of -8.3 mV. The conjugate exhibited significant cytotoxicity against CRC cells, with notable apoptosis induction and ROS generation in EGFR-positive/KRAS mutant SW-480 cells, surpassing the effects observed with bare Cet and EMNP-PEG controls. The nuclear factor erythroid 2-related factor 2/Kelch-like ECH-related protein 1 (Nrf2-Kaep1) gene expression analysis by real-time PCR showed that cells treated with EMNP-PEG-Cet exhibited a noteworthy decrease in Nrf2 expression and a simultaneous increase in Keap1 expression compared to those treated with free Cet. Conclusion: These findings highlight the potential of ROS-mediated apoptosis induction to enhance the cytotoxicity of Cet in EGFR-positive/KRAS mutant CRC cells, offering new avenues for overcoming drug resistance mechanisms in metastatic CRC.
- Open Access
- 29 August 2023
- Published by Maad Rayan Publishing Company in BioImpacts
- Vol. 14 (1) , 1-5
Targeting long non-coding RNAs as new modulators in anti-EGFR resistance mechanisms
Epidermal growth factor receptor (EGFR) is a cell surface protein that plays a vital role in regulating cell growth and division. However, certain tumors, such as colorectal cancer (CRC), can exhibit an overexpression of EGFR, resulting in uncontrolled cell growth and tumor progression. To address this issue, therapies targeting and inhibiting EGFR activity have been developed to suppress cancer growth. Nevertheless, resistance to these therapies poses a significant obstacle in cancer treatment. Recent research has focused on comprehending the underlying mechanisms contributing to anti-EGFR resistance and identifying new targets to overcome this striking challenge. Long non-coding RNAs (lncRNAs) are a class of RNA molecules that do not encode proteins but play pivotal roles in gene regulation and cellular processes. Emerging evidence suggests that lncRNAs may participate in modulating resistance to anti-EGFR therapies in CRC. Consequently, combining lncRNA targeting with the existing treatment modalities could potentially yield improved clinical outcomes. Illuminating the involvement of lncRNAs in anti-EGFR resistance mechanisms of cancer cells can provide valuable insights into the development of novel anti-EGFR therapies in several solid tumors.
- 29 August 2023
- Published by Maad Rayan Publishing Company in BioImpacts
- Vol. 14 (1) , 1-5
Open AccessTargeting long non-coding RNAs as new modulators in anti-EGFR resistance mechanisms
Epidermal growth factor receptor (EGFR) is a cell surface protein that plays a vital role in regulating cell growth and division. However, certain tumors, such as colorectal cancer (CRC), can exhibit an overexpression of EGFR, resulting in uncontrolled cell growth and tumor progression. To address this issue, therapies targeting and inhibiting EGFR activity have been developed to suppress cancer growth. Nevertheless, resistance to these therapies poses a significant obstacle in cancer treatment. Recent research has focused on comprehending the underlying mechanisms contributing to anti-EGFR resistance and identifying new targets to overcome this striking challenge. Long non-coding RNAs (lncRNAs) are a class of RNA molecules that do not encode proteins but play pivotal roles in gene regulation and cellular processes. Emerging evidence suggests that lncRNAs may participate in modulating resistance to anti-EGFR therapies in CRC. Consequently, combining lncRNA targeting with the existing treatment modalities could potentially yield improved clinical outcomes. Illuminating the involvement of lncRNAs in anti-EGFR resistance mechanisms of cancer cells can provide valuable insights into the development of novel anti-EGFR therapies in several solid tumors.